Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps - PubMed (original) (raw)
Review
Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
Raul D Santos et al. Atherosclerosis. 2019 Mar.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and includes a spectrum of abnormalities ranging from steatosis to cirrhosis. In this review, we address recent evidence and limitations of studies that evaluated the association of NAFLD with atherosclerotic cardiovascular disease. NAFLD is considered an ectopic fat deposit associated with metabolic (insulin resistance, hyperglycemia and dyslipidemia), inflammatory, coagulation and blood pressure disturbances. Prospective studies have associated NAFLD presence and severity, particularly steatohepatitis and fibrosis, with an increased risk of cardiovascular disease. However, these studies are limited by heterogeneity concerning NAFLD diagnostic criteria and disease severity stratification, as well as by the presence of confounding factors. In addition, genetic variants predisposing to NAFLD, such as the PNPLA3 I148M mutation, were not consistently associated with an increased risk of cardiovascular events. Therefore, currently, it is not possible to prove a causal relation between NAFLD and cardiovascular disease. Furthermore, there is presently no evidence that NAFLD diagnosis can be used as a tool to improve cardiovascular risk stratification and modify treatment. Specific treatments for NAFLD are being developed and must be tested prospectively in adequately designed trials to determine the potential of reducing both hepatic and cardiovascular diseases and to prove whether NAFLD is indeed a cause of atherosclerosis.
Keywords: Atherosclerosis; Diabetes; Genetics; Hepatic steatosis; Non-alcoholic fatty liver disease; Obesity; Risk stratification.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
- Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk.
Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C. Pacifico L, et al. World J Gastroenterol. 2011 Jul 14;17(26):3082-91. doi: 10.3748/wjg.v17.i26.3082. World J Gastroenterol. 2011. PMID: 21912450 Free PMC article. Review. - Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter.
Chiriac S, Stanciu C, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Cuciureanu T, Huiban L, Muzica CM, Zenovia S, Nastasa R, Trifan A. Chiriac S, et al. Can J Gastroenterol Hepatol. 2021 Jan 12;2021:6696857. doi: 10.1155/2021/6696857. eCollection 2021. Can J Gastroenterol Hepatol. 2021. PMID: 33505944 Free PMC article. Review. - Ectopic fat, insulin resistance and non-alcoholic fatty liver disease.
Byrne CD. Byrne CD. Proc Nutr Soc. 2013 Nov;72(4):412-9. doi: 10.1017/S0029665113001249. Epub 2013 May 14. Proc Nutr Soc. 2013. PMID: 23668723 Review. - Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F, Sninsky JJ, Baca AM, Superko HR, Portillo Sanchez P, Biernacki D, Maximos M, Lomonaco R, Orsak B, Suman A, Weber MH, McPhaul MJ, Cusi K. Bril F, et al. J Clin Endocrinol Metab. 2016 Feb;101(2):644-52. doi: 10.1210/jc.2015-3111. Epub 2015 Dec 16. J Clin Endocrinol Metab. 2016. PMID: 26672634 - Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, Ratziu V, Lonardo A. Loria P, et al. Atherosclerosis. 2014 Jan;232(1):99-109. doi: 10.1016/j.atherosclerosis.2013.10.030. Epub 2013 Nov 6. Atherosclerosis. 2014. PMID: 24401223 Review.
Cited by
- Strategy for treating MAFLD: Electroacupuncture alleviates hepatic steatosis and fibrosis by enhancing AMPK mediated glycolipid metabolism and autophagy in T2DM rats.
Duan H, Song S, Li R, Hu S, Zhuang S, Liu S, Li X, Gao W. Duan H, et al. Diabetol Metab Syndr. 2024 Sep 11;16(1):218. doi: 10.1186/s13098-024-01432-7. Diabetol Metab Syndr. 2024. PMID: 39261952 Free PMC article. - Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals.
Souza M, Diaz I, Al-Sharif L. Souza M, et al. Hepatol Int. 2024 Oct;18(5):1396-1415. doi: 10.1007/s12072-024-10716-z. Epub 2024 Aug 8. Hepatol Int. 2024. PMID: 39117942 Review. - Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting.
Linero PL, Castilla-Guerra L. Linero PL, et al. Eur Cardiol. 2024 May 9;19:e02. doi: 10.15420/ecr.2023.19. eCollection 2024. Eur Cardiol. 2024. PMID: 38807854 Free PMC article. Review. - Influence of nonalcoholic fatty liver disease severity on carotid adventitial vasa vasorum.
León-Mengíbar J, Sánchez E, Herrerías F, De La Fuente MC, Santamaría M, Valdivielso JM, Bermúdez-López M, Castro E, Pallarés J, Matias-Guiu X, Vilardell F, Caixàs A, Bueno M, Martí R, Lecube A. León-Mengíbar J, et al. Front Endocrinol (Lausanne). 2024 May 7;15:1366015. doi: 10.3389/fendo.2024.1366015. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38774226 Free PMC article. - Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies.
Al Hashmi K, Giglio RV, Pantea Stoian A, Patti AM, Al Waili K, Al Rasadi K, Ciaccio M, Rizzo M. Al Hashmi K, et al. Front Nutr. 2024 Mar 19;11:1355732. doi: 10.3389/fnut.2024.1355732. eCollection 2024. Front Nutr. 2024. PMID: 38567250 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical